Endocrinology

Help Shape the Future of Denosumab Treatment

As biosimilars enter the denosumab landscape, your perspective as a healthcare provider is critical in understanding what factors influence treatment decisions. This brief survey explores your views on reimbursement considerations, coding challenges, switching comfort, and drivers of biosimilar choice. As a thank you, by completing the survey, you’ll be entered into a drawing for a chance to win a $200 gift card.

Take the survey now and make your voice heard

Latest News

nt Semaglutide Quells "Food Noise" Among Adults on Treatment for Obesity and Overweight / image credit freshidea/stock.adobe.com
Semaglutide Quells "Food Noise," Improves Mental Health Among Adults on Treatment for Obesity and Overweight

September 17th 2025

EASD 2025: After initiating treatment with semaglutide, the number of people who reported experiencing constant thoughts about food throughout the day declined by 46%.

Amylin Injectable Cagrilintide Demonstrates Weight Loss of 11.8% in Late-Stage Trial: Novo Nordisk Update / image credit Timothy Garvey, MD courtesy of University of Alabama at Birmingham
Amylin Injectable Cagrilintide Demonstrates Weight Loss of 11.8% in Late-Stage Trial: Novo Nordisk Update

September 16th 2025

Real-Time Continuous Glucose Monitoring Lowers Risk of Large for Gestational Age Infants in Gestational Diabetes / Image credit: ©arturfoto/AdobeStock
Real-Time Continuous Glucose Monitoring Lowers Risk of Large for Gestational Age Infants in Gestational Diabetes

September 16th 2025

Smoking Linked to Increased Risk of All Subtypes of Type 2 Diabetes / image credit Karolinska Institutet
Smoking Linked to Increased Risk of All Subtypes of Type 2 Diabetes

September 16th 2025

FDA Approves Automated Insulin Delivery System for Adults With T2D: Daily Dose / image credit: ©New Africa/AdobeStock
FDA Approves Automated Insulin Delivery System for Adults With T2D: Daily Dose

September 16th 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.